Notice of Intent to Sole Source – Cytiva

Active

Contract Opportunity

This acquisition is for SmartRedux Sepax 2 protocol software upgrade for the Sepax C-PRO equipment that will be used in manufacturing research and development of cell-based therapies for patients enrolled on NIH sponsored clinical trials at the National Institutes of Health (NIH) Clinical Center (CC).

• Product Service Code: 6515 – Medical Instruments, Equipment, and Supplies

• NAICS Code: 512310 – Software Publishers

• Place of Performance: Bethesda, MD 20892 USA

POTS: 26-001651

Description:

This is a notice of intent, not a request for a quotation. A solicitation document will not be issued and quotations will not be requested.

The National Institutes of Health (NIH) intends to award a fixed price purchase order to Global Life Sciences Solutions, on a firm fixed price sole source award basis to provide software upgrades to the National Institutes of Health.

Global Life Sciences Solutions USA LLC is doing business as Cytiva. Cytiva is the original equipment

manufacturer and the sole distributor of their equipment and supplies. The FDA mandates that all

repairs and maintenance are carried out by qualified technicians. Cytiva/Global Life Sciences Solutions

USA LLC is the only source of technicians qualified to service these devices and upgrade their software.

This acquisition is being conducted using policies unique to the Federal Acquisition Regulation (FAR) Part 13 – Simplified Acquisition Procedures, Subpart 13.106-1(b)(1), For purchases not exceeding the simplified acquisition threshold (SAT), contracting officers may solicit from one source if the contracting officer determines that the circumstance of the contract action deem only one source reasonably available. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirements of FAR Part 6-Competition Requirements.

Interested parties may identify their interest and capabilities in response to this posting. The determination by the Government not to compete the proposed requirement based upon responses to this notice is solely within the discretion of the Government.

Comments to this announcement, referencing this posting number, may be submitted to the NIH, Clinical Center, Office of Purchasing and Contracts, prior to the closing date specified in this announcement, to the attention of Kristin Nagashima, Contract Specialist via email to Kristin.nagashima@nih.gov by March 26, 2026 at 11am EST.

Attachments/Links